VYRIAD
Live / Applied — Opposition pending (as of 07 Nov 2024)
What this means for you
Not registered yet, but its 08 Aug 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98122765
- Mark type
- Stylized text
- Filed
- 08 Aug 2023
- Published for opposition
- 08 Oct 2024
- Attorney of record
- MICHELLE L. ZIMMERMANN
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medicinal preparations for use in oncology; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely, cancer and cardiovascular diseases and heritable genetic diseases; pharmaceutical preparations for treatment of genetic and heritable genetic diseases; cellular pharmaceutical preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T) cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; pharmaceutical preparations for use in oncology; all of the foregoing to exclude infectious diseases
- Class 042 — Scientific and technological services: Medical and scientific research and development in the fields of cancer treatment and oncolytic virotherapy; research and development of bio-pharmaceuticals for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medical and scientific research in the fields of genetics and oncology; research and development of technology in the fields of stem cells and stem cell therapy for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; development of genetic therapies and chimeric antigen receptor cell (CAR-T) cell therapies for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; scientific research and development of cell therapies, namely, chimeric antigen receptor T-cells (CAR-T) to cure solid tumor cancers and other cancers; medical and scientific research services in the fields of genetics, cell therapy, oncology, immuno-oncology; all of the foregoing to exclude infectious diseases
Owner
- Vyriad, Inc., Rochester, MN, US
- Vyriad, Inc., Rochester, MN, US
Prosecution history
- 07 May 2025 — OPPOSITION DISMISSED NO. 999999
- 07 Nov 2024 — OPPOSITION INSTITUTED NO. 999999
- 07 Nov 2024 — OPPOSITION PAPERS RECEIVED AT TTAB
- 04 Nov 2024 — POST PUBLICATION AMENDMENT - ENTERED
- 21 Oct 2024 — ASSIGNED TO PETITION STAFF
- 08 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Oct 2024 — PUBLISHED FOR OPPOSITION
- 03 Oct 2024 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 18 Sept 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 Jun 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Jun 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 Jun 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 10 Apr 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Apr 2024 — NON-FINAL ACTION E-MAILED